Althian is participating in a trial of a breakthrough therapy, as designated by FDA

Althian is currently participating in a phase III breast cancer clinical trial. We are glad to know that the molecule being studied in this trial, Abemaciclib, has been granted a breakthrough therapy designation by the FDA for patients with refractory hormone receptor-positive advanced or metastatic breast cancer.

This molecule has also showed clinical activity in patients with other types of cancer, such as non-small cell lung cancer, glioblastoma, and melanoma.

For more information about these news, you can check the complete article at Science Daily, referenced below.

American Association for Cancer Research. “Investigational CDK4/6 inhibitor abemaciclib is active against a range of cancer types.” ScienceDaily. ScienceDaily, 23 May 2016. <www.sciencedaily.com/releases/2016/05/160523083605.htm>.

Comments are closed.

Visit Us On FacebookVisit Us On Linkedin